Plain-English translation of NCT07432958 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 study testing a new medication called to help people with Parkinson's disease who experience "OFF" times—periods when their medication stops working well and symptoms return. You would take this treatment along with your current levodopa, and researchers will compare it to a placebo to see if it reduces how long these symptom breaks last.
Many people with Parkinson's disease experience unpredictable gaps in their medication's effectiveness, even when taking levodopa regularly. This trial is testing whether adding this medication could help smooth out those fluctuations and give you more stable control of your symptoms throughout the day.
You likely qualify if…
You likely don't qualify if…
The study lasts about 12 weeks total. You'll have a screening visit, then a 4-week period where your Parkinson's medications stay the same, followed by 8 weeks where you'll take either the new medication (at one of two doses), or a placebo—and neither you nor the study staff will know which. During the treatment period, your doctors can make small adjustments to your levodopa if needed. You'll track your symptom patterns in a home diary to help measure how the treatment is working.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States